While these enhancements are not specifically directed towards the treatment of MM, CD38 knockout via CRISPR/Cas9 resulted in higher mitochondrial respiratory activity, with improved persistence in ex vivo expanded peripheral blood NK cells directed against MM cells [134]. The gene discussed is CD38; the disease is Miyoshi myopathy.